Jackson Thornton Wealth Management LLC Trims Stock Position in Eli Lilly and Company $LLY

Jackson Thornton Wealth Management LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 11.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 644 shares of the company’s stock after selling 86 shares during the quarter. Jackson Thornton Wealth Management LLC’s holdings in Eli Lilly and Company were worth $501,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the company. DecisionMap Wealth Management LLC raised its holdings in shares of Eli Lilly and Company by 111.4% in the 2nd quarter. DecisionMap Wealth Management LLC now owns 1,264 shares of the company’s stock worth $985,000 after purchasing an additional 666 shares during the period. Divergent Planning LLC purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $1,548,000. Syntegra Private Wealth Group LLC raised its holdings in shares of Eli Lilly and Company by 27.0% in the 2nd quarter. Syntegra Private Wealth Group LLC now owns 1,311 shares of the company’s stock worth $1,022,000 after purchasing an additional 279 shares during the period. Liberty One Investment Management LLC raised its holdings in shares of Eli Lilly and Company by 4.7% in the 2nd quarter. Liberty One Investment Management LLC now owns 37,454 shares of the company’s stock worth $29,196,000 after purchasing an additional 1,685 shares during the period. Finally, Klingman & Associates LLC raised its holdings in shares of Eli Lilly and Company by 18.3% in the 2nd quarter. Klingman & Associates LLC now owns 2,232 shares of the company’s stock worth $1,740,000 after purchasing an additional 346 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 0.8%

NYSE:LLY opened at $808.88 on Tuesday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The business’s 50 day moving average is $756.56 and its two-hundred day moving average is $766.20. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a market cap of $765.57 billion, a PE ratio of 52.87, a P/E/G ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the business posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LLY. Wall Street Zen downgraded Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 20th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the company an “overweight” rating in a research note on Thursday, October 9th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Insider Activity

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO David A. Ricks acquired 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 4,514 shares of company stock worth $2,894,841 over the last ninety days. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.